AURA Takes you to the home page

Aberdeen University Research Archive >
6 - All research >
All research >

Please use this identifier to cite or link to this item:

This item has been viewed 1 times in the last year. View Statistics

Files in This Item:

File Description SizeFormat
Armstrong 2009.pdf435.31 kBAdobe PDFView/Open
Title: Surgical treatments for men with benign prostatic enlargement : cost effectiveness study
Authors: Armstrong, Nigel
Vale, Luke David
Deverill, Mark
Nabi, Ghulam
McClinton, Sam
N'Dow, James Michael Olu
Pickard, Robert
BPE Study Group
University of Aberdeen, School of Medicine & Dentistry, Division of Applied Health Sciences
Keywords: Cost-benefit Analysis
Prostatic Hyperplasia
Surgical Procedures, Minimally Invasive
Transurethral Resection of Prostate
Issue Date: 16-Apr-2009
Publisher: BMJ
Citation: Armstrong, N., Vale, L., Deverill, M., Nabi, G., McClinton, S., N'Dow, J., and Pickard, R. (2009). Surgical treatments for men with benign prostatic enlargement : cost effectiveness study. BMJ, 338, pp. 1187-1190.
Abstract: Objective To determine which surgical treatment for lower urinary tract symptoms suggestive of benign prostate enlargement is cost effective. Design Care pathways describing credible treatment strategies were decided by consensus. Cost-utility analysis used Markov modelling and Monte Carlosimulation. Data sources Clinical effectiveness data came from a systematic review and an individual level dataset. Utility values came from previous economic evaluations. Costs were calculated from National Health Service (NHS) and commercial sources. Methods The Markov model included parameters withassociated measures of uncertainty describing health states between which individuals might move at three monthly intervals over 10 years. Successive annual cohorts of 25 000 men were entered into the model and the probability that treatment strategies were cost effective was assessed with Monte Carlo simulation with 10 000 iterations. Results A treatment strategy of initial diathermy vaporisation of the prostate followed by endoscopic holmium laser enucleation of the prostate in case of failure to benefit or subsequent relapse had an 85% probability of being cost effective at a willingness to pay value of £20 000 (€21 595, $28 686)/quality adjusted life year (QALY) gained. Other strategies with diathermy vaporisation as the initial treatment were generally cheaper and more effective than the current standard of transurethral resection repeated once if necessary. The use of potassium titanyl phosphate laser vaporisation incurred higher costs and was less effective than transurethral resection, and strategies involving initial minimally invasive treatment with microwave thermotherapy were not cost effective. Findings were unchanged by wide ranging sensitivity analyses. Conclusion The outcome of this economic model should be interpreted cautiously because of the limitations of the data used. The finding that initial vaporisation followed by holmium laser enucleation for failure or relapse might be advantageous both to men with lower urinary tract symptoms and to healthcare providers requires confirmation in a good quality prospective clinical trial before any change in current practice. Potassium titanyl phosphate laser vaporisation was unlikely to be cost effective in our model, which argues against its unrestricted use until further evidence of effectiveness and cost reduction is obtained.
ISSN: 0959-8138
Appears in Collections:Applied Health Sciences research
All research

SFX Query

Items in AURA are protected by copyright, with all rights reserved, unless otherwise indicated.


The University of Aberdeen
King's College
AB24 3FX
Tel: +44 (0)1224-272000